Provided by Tiger Trade Technology Pte. Ltd.

Agree

76.75
+0.24000.31%
Post-market: 76.750.00000.00%18:27 EST
Volume:1.97M
Turnover:151.03M
Market Cap:8.82B
PE:44.83
High:77.16
Open:77.00
Low:75.44
Close:76.51
52wk High:79.65
52wk Low:68.98
Shares:114.93M
Float Shares:108.37M
Volume Ratio:1.59
T/O Rate:1.82%
Dividend:3.05
Dividend Rate:3.98%
EPS(TTM):1.71
EPS(LYR):1.78
ROE:3.48%
ROA:2.33%
PB:1.55
PE(LYR):43.12

Loading ...

Agree Realty Signals Confident Growth in 2026 Outlook

TIPRANKS
·
1 hour ago

Analysts’ Top Real Estate Picks: Scentre Group (STGPF), Agree Realty (ADC)

TIPRANKS
·
2 hours ago

Agree Realty's Q4 Confirms Acceleration Signal

Benzinga_recent_news
·
5 hours ago

Agree Realty Is Maintained at Buy by Stifel

Dow Jones
·
Yesterday

Evercore ISI Sticks to Their Buy Rating for Agree Realty (ADC)

TIPRANKS
·
Yesterday

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

GlobeNewswire
·
Yesterday

Sutro Biopharma Highlights ADC Platform in New Presentation

TIPRANKS
·
Yesterday

GUIDANCE: (ADC) Agree Realty Expects Full Year 2026 AFFO Range $4.54 - $4.58

MT Newswires Live
·
Yesterday

Agree Realty Q4 net income per share rises

Reuters
·
Yesterday

Agree Realty reports Q4 AFFO $1.11, consensus $1.10

TIPRANKS
·
Yesterday

Agree Realty sees FY26 AFFO $4.54-$4.58, consensus $4.53

TIPRANKS
·
Yesterday

ADC Q4 net income attributable to common stockholders at USD 54.18 million, up 25%

Reuters
·
Yesterday

Agree Realty Q4 FFO $1.11 Beats $1.10 Estimate, Sales $190.489M Beat $185.501M Estimate

Benzinga
·
Yesterday

BRIEF-Agree Realty Q4 Core FFO Per Share USD 1.1

Reuters
·
Yesterday

Agree Realty Outlook FY Adjusted Ffo per Share USD 4.54-4.58

THOMSON REUTERS
·
Yesterday

Agree Realty: on Track to Achieve 2026 Affo per Share Guidance of $4.54 to $4.58

THOMSON REUTERS
·
Yesterday

Agree Realty Q4 Core Ffo USD 126.8 Million

THOMSON REUTERS
·
Yesterday

U.S. Earnings Preview: After Market Close Feb. 10

Dow Jones
·
Yesterday

Defence Therapeutics Refines Accum ADC Strategy With New Scientific Advisory Board

TIPRANKS
·
Feb 10

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

GlobeNewswire
·
Feb 10